Procysbi FDA Approval History
FDA Approved: Yes (First approved April 30, 2013)
Brand name: Procysbi
Generic name: cysteamine bitartrate
Dosage form: Delayed-Release Capsules
Company: Raptor Pharmaceutical Corp.
Treatment for: Nephropathic Cystinosis
Procysbi (cysteamine bitartrate) is a cystine depleting agent indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.
Development Timeline for Procysbi
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.